NR4A1 and breast carcinoma: Systemic therapy for nonmetastatic breast cancer is determined by subtype: patients with hormone-receptor-positive tumors receive endocrine therapy, and a minority receive chemotherapy as well; patients with ERBB2-positive tumors receive ERBB2-targeted antibody or small-molecule inhibitor therapy combined with chemotherapy; and patients with triple-negative tumors receive chemotherapy [19].